Click on headlines below to download research
Executive interview
Nano Dimension - executive interview | 08/02/2023
Nano Dimension offers equipment for additive manufacture of high-performance electronic devices, complex 3D ceramic and metal objects as well as miniature…
Litigation settlement concluded
Nanoco Group | 08/02/2023
Nanoco Group has signed the final agreements to settle the litigation with Samsung on a no-fault basis for the alleged infringement of the group's intellectual…
Lithium price upgrade calls for higher valuation
Lithium Power International | 08/02/2023
We have raised our near-term lithium price expectations to reflect the current supply/demand cycle and upgraded our long-run (post 2031) price forecasts…
Stronger-than-expected revenue growth in Q3
Accsys Technologies | 08/02/2023
Accsys showed strong revenue growth of 32% in 9M23, driven by higher sales prices (to mitigate input pressure) and a recovery in volumes in Q323 compared…
Space travel in the metaverse
Vection Technologies | 07/02/2023
Vection Technologies (VR1) reported A$4.6m in Q223 receipts, up A$0.2m q-o-q. Recent announcements of the company’s selection to develop virtual…
Growth-oriented review poised to be announced
Foxtons Group | 07/02/2023
FY22 was a robust year for Foxtons with revenue up 11%, but the short-term outlook is less certain for recessionary reasons. However, the outlook remains…
Component shortages causing delivery delays
Filtronic | 07/02/2023
As flagged in Filtronic’s January trading update, demand for 5G mobile communications infrastructure and work for new customers drove 5% year-on-year…
Strong revenue growth and improving margin
Ebiquity | 07/02/2023
Ebiquity’s year-end trading update confirms that revenue continued to grow strongly in H222, delivering a 20% improvement for the full year, with…
Revenues running in line with H222
Numis | 07/02/2023
The trends seen in Numis’s H222 have continued in the first four months of FY23. Capital markets activity and revenues have been subdued but the…
Dollars in the bank with CMS reimbursement
Respiri | 07/02/2023
In a positive development for its US commercial strategy, Respiri has announced receipt of its first reimbursement claims from the Centers for Medicare…
Q323 update supports full-year forecasts
Renewi | 06/02/2023
Renewi is a leader in waste and recycling sectors and is well positioned in the emerging circular economy. Following the recently completed private equity…
Encouraging positive efficacy signals from OATH trial
Context Therapeutics | 06/02/2023
Context Therapeutics has announced that two patients enrolled in the Phase II OATH trial (ONA-XR+anastrozole in advanced endometrial cancer) have achieved…
Income and outperformance in uncertain times
JPMorgan Global Growth & Income | 06/02/2023
JPMorgan Global Growth & Income (JGGI) invests in long-term structural winners, although in these uncertain times, managers Helge Skibeli, Tim Woodhouse…
Pluses and minuses of high energy costs
Light Science Technologies | 06/02/2023
In December, Light Science Technologies Holdings (LSTH) noted that high input costs have resulted in strong interest in the group’s controlled environment…
On track to start Phase IIb XanaMIA study
Actinogen Medical | 06/02/2023
Actinogen’s recent quarterly update confirmed that the company remains on track to start US recruitment in H1 CY23 for its six-month, placebo-controlled…
Growing income and portfolio outperformance
Picton Property Income | 03/02/2023
Picton Property Income’s (PCTN’s) Q323 report shows asset management and leasing activity continuing to grow rental income. This provided a…
Continuing to do ‘what it says on the tin’
Martin Currie Global Portfolio Trust | 02/02/2023
Martin Currie Global Portfolio Trust (MNP) has been managed by Zehrid Osmani since 1 October 2018. Despite a tough period of absolute and relative underperformance…
Sustainable in several senses
Newmont Corporation | 02/02/2023
Newmont will update guidance for 2023 when it releases Q4 results on 23 February 2023. We anticipate a strong close to 2022 (production up 6% quarter on…
Portfolio expansion with new in-licensing deal
AFT Pharmaceuticals | 02/02/2023
AFT Pharmaceuticals continues to strengthen its R&D pipeline with the announced in-licensing agreement with Latitude Pharmaceuticals (a US-based contract…
Executive interview
BlueBet Holdings - executive interview | 02/02/2023
BlueBet Holdings is an online Australian wagering operator founded in 2015. It offers betting products on 31 sports in Australia and internationally via…
Funded past near-term inflection points
Paradigm Biopharma | 02/02/2023
Cash flow figures from Paradigm Biopharmaceuticals’ latest update show that it remains funded past key near-term inflection points. In Q223, management…
Completion of Vodafone Hungary acquisition
4iG | 02/02/2023
4iG closed the acquisition of a 51% stake in Vodafone Hungary on 31 January, via its subsidiary Antenna Hungária, and yesterday announced the new…
Shareholders approve Yamana transaction
Pan American Silver | 02/02/2023
Pan American Silver (PAAS) has reported that its shareholders approved the proposed share issue to acquire all outstanding Yamana Gold shares as part of…
Meeting guidance for 10th consecutive year
Endeavour Mining | 01/02/2023
In preparation for FY22 results on 9 March, Endeavour has released preliminary operational results. Q422 saw a 4% increase in gold production, totalling…
Progress made against KPIs
CLIQ Digital | 01/02/2023
CLIQ Digital’s FY22 update showed strong year-on-year growth across all KPIs, as it continues to roll out its subscription-based bundled-content…
Reinvestment period with increased R&D focus
Kazia Therapeutics | 01/02/2023
Kazia Therapeutics has released its Q223 activity report and provided a business update for the quarter. Q2 was marked by increased preclinical efforts…
Expansion of presence in satcom market
Filtronic | 01/02/2023
Filtronic has announced a contract win worth more than £2.0m with a new customer in the satellite communications equipment market, demonstrating its…
Pipeline advancement to support growth plan
Incannex Healthcare | 01/02/2023
Incannex Healthcare’s Q223 cash flow report provided the period’s key operational highlights. Notable activities include the start of a bioavailability…
Elacestrant approval shot in the arm for ELONA trial
Context Therapeutics | 31/01/2023
On 27 January, the US FDA approved Stemline Therapeutics’ (wholly owned US subsidiary of the Menarini group) elacestrant (Orserdu) as second-line…
Record receipts and restructuring
SenSen Networks | 30/01/2023
SenSen Networks (SNS) maintained its streak of record year-on-year cash receipts in Q223, with customer receipts up 70% against Q222 to A$2.6m. SNS continues…
Unfazed by challenging environment
CentralNic Group | 30/01/2023
CentralNic’s FY22 update confirmed accelerating momentum towards the end of the year, with revenue and adjusted EBITDA ahead of our forecasts, which…
Back to steady growth
Treatt | 30/01/2023
Treatt’s AGM trading update suggests a more normal and steady pattern of trading has resumed, following the setbacks that caused the profit warning…
Resilience in a more difficult macro environment
YouGov | 27/01/2023
YouGov’s trading update covering the six months to end January confirms that the group is on track to meet the full year market revenue consensus…
Confidence in long-term successful strategy
Finsbury Growth & Income Trust | 27/01/2023
Finsbury Growth & Income Trust (FGT) has been managed by Nick Train for more than two decades. The trust’s 2021 and 2022 underperformance should…
Robust core and executing in the US
BlueBet Holdings | 27/01/2023
BlueBet’s (BBT’s) Q223 results highlighted a robust performance in its primary geography, Australia, against a more competitive backdrop. Good…
Promising signs for 2023
MotorK | 26/01/2023
For FY22, MotorK reported a record Q4, driven by its focus on higher-value enterprise contracts, the launch of its SparK platform and the continued migration…
Trading recap highlights continued market traction
Respiri | 26/01/2023
Respiri has released its Q223 quarterly activity report and provided a business update for the quarter. The second quarter was characterised by improving…
Better trading and acquisition drive upgrades
discoverIE Group | 26/01/2023
discoverIE’s Q323 trading update confirmed continued good momentum, with FY23 underlying earnings tracking ahead of board expectations. The company…
Searching for mispriced quality
Henderson EuroTrust | 25/01/2023
Henderson EuroTrust (HNE) provides relatively concentrated exposure to a portfolio of continental European (ex-UK) equities. The trust has been solely…
Strong execution resulting in operating profitability
Basilea Pharmaceutica | 25/01/2023
On the heels of management’s January upward guidance revision, continued strong execution of Basilea’s outlined strategic plan (February 2022)…
Maxigesic IV expands into East European markets
AFT Pharmaceuticals | 25/01/2023
AFT Pharmaceuticals has announced an exclusive licensing and distribution agreement for the Maxigesic intravenous (IV) formulation with Salus Pharmaceuticals…
New use case in manufacturing opening up?
WANdisco | 24/01/2023
WANdisco’s deal flow momentum continues, with a $9m contract with a European consumer goods and manufacturing company. This win is notable in that…
Urgent pivot required following Bioasis deal fallout
Midatech Pharma | 24/01/2023
Midatech has announced that its shareholders have not approved the acquisition of Bioasis Technologies at the company’s annual general meeting (AGM),…
Phase II milestone as licensing potential nears
Ultimovacs | 23/01/2023
Ultimovacs has announced that patient enrolment has been completed (n=118) for the ongoing Phase II NIPU study investigating the company’s lead cancer…
NanaBis development centre stage in 2023
Medlab Clinical | 23/01/2023
As Medlab Clinical moves into 2023, the expected commencement of a Phase III trial for NanaBis (the company’s cannabinoid based analgesic therapy)…
Strong royalty performance
Round Hill Music Royalty Fund | 23/01/2023
A healthy music-streaming market coupled with Round Hill Music Royalty Fund’s (RHMRF’s) attractive portfolio resulted in a strong net publisher’s…
Proxy advisors support Yamana vote
Pan American Silver | 20/01/2023
Pan American Silver (PAAS) has reported preliminary operational results for FY22. Consolidated silver and gold production of 18.5Moz and 552.5koz were…
Update on takeover process
EMIS Group | 20/01/2023
EMIS Group’s year-end update confirms that FY22 revenue and adjusted operating profit were in line with the board’s expectations and it closed…
Strong finish to FY22 prompts further upgrade
4imprint Group | 20/01/2023
4imprint’s update shows the group continuing to trade strongly through Q422 and we again upgrade estimates. FY22 revenue will be $1.14bn, or 3% ahead…
Q4 highlights confirm continued Vyzulta growth
Nicox | 19/01/2023
Nicox has provided a preliminary Q422 update, reporting a c 38% y-o-y increase in FY22 net royalty payments to €3.3m, including a c 100% y-o-y elevation…
FY22 wrap offers key operational takeaways
OpGen | 19/01/2023
OpGen has announced preliminary FY22 results and provided a business update ahead of the detailed FY22 report expected in March 2023. Group revenue came…
Progressing on all fronts
Creo Medical | 19/01/2023
2022 was an eventful year for Creo Medical, as it progressed on all fronts of its ‘Build, Buy and Partner’ strategy. The period was marked…
In line, with good momentum
Secure Trust Bank | 19/01/2023
In its FY22 post-close trading update, Secure Trust Bank (STB) announced that business has been trading in line with management expectations and with good…
Strong cash performance and special dividend
Centaur Media | 19/01/2023
Centaur’s year-end trading update indicates revenue of at least £41m and an EBITDA margin of more than 19.5%. Our FY22e EBITDA, PBT and EPS…
SUPR takes majority interest in indirect portfolio
Supermarket Income REIT | 19/01/2023
Supermarket Income REIT (SUPR) has acquired an additional 25.5% beneficial interest in the Sainsbury’s Reversion Portfolio (SRP) from its joint venture…
Order momentum maintained in Q422
Esker | 19/01/2023
Esker’s Q422 revenue update confirmed that the company hit the mid-point of its revenue guidance for FY22, despite the already flagged slowdown in…
Progressing the opportunity in anxiety treatment
Incannex Healthcare | 19/01/2023
Following continued patient enrolment in Incannex’s ongoing Australian Phase II Psi-GAD1 study (ACTRN12621001358831), management has announced the…
First Phase II patient enrolled is clinical milestone
Oryzon Genomics | 18/01/2023
Oryzon Genomics has announced that it has enrolled the first patient into its collaborative Phase II trial investigating the use of its lead LSD1 inhibitor,…
Mesdopetam Phase IIb top-line data
IRLAB Therapeutics | 18/01/2023
IRLAB Therapeutics has announced top-line data from its Phase IIb trial investigating mesdopetam as a treatment for Parkinson’s disease levodopa-induced…
European collaboration MOU signed
Provaris Energy | 18/01/2023
The memorandum of understanding (MOU) signed with Norwegian Hydrogen is the latest significant step in Provaris Energy’s development of a cost-effective…
FIND milestone payment triggered
OpGen | 18/01/2023
OpGen has announced that its Unyvero A30 RQ platform has achieved certain key initial milestones under its R&D collaboration agreement with FIND (a global…
Upside potential from successful project funding
Baker Steel Resources Trust | 18/01/2023
Baker Steel Resources Trust (BSRT) posted an NAV total return of -16.3% in FY22, which was mostly a result of the de-rating of recently floated holdings…
A rewarding FY22 for core technology arsenal
Creo Medical | 18/01/2023
Creo Medical has announced its FY22 trading update and outlook for the year ahead. FY22 was a busy period marked by several commercial developments for…
Ebiquity executive interview: Ebiquity's growing capabilities and opportunities
Ebiquity executive interview: Ebiquity’s growing capabilities and opportunities | 17/01/2023
Ebiquity is a leading, independent global media consultancy, working for over 70 of the world’s 100 leading brands to optimise their media investments.…
Ebiquity executive interview: The role of responsible media
Ebiquity executive interview: The role of responsible media | 17/01/2023
Ebiquity is a leading, independent global media consultancy, working for over 70 of the world’s 100 leading brands to optimise their media investments.…
Ebiquity executive interview: Key issues for brand advertisers in 2023
Ebiquity executive interview: Key issues for brand advertisers in 2023 | 17/01/2023
Ebiquity is a leading, independent global media consultancy, working for over 70 of the world’s 100 leading brands to optimise their media investments.…
Executive interview
The Metals Company - executive interview | 17/01/2023
In this interview we talk to Gerard Barron, executive chairman and CEO of The Metals Company, which is looking to retrieve polymetallic nodules rich in…
Vetting the pet health opportunity
VolitionRx | 17/01/2023
While pets are increasingly being ‘humanized’, their healthcare has lagged advancements seen on the human side. With the COVID-19 pandemic…
Next-generation implant chip highlighted
Pixium Vision | 17/01/2023
Pixium has announced the publication of data in three peer reviewed journals highlighting that its second-generation (2G) Prima sub-retinal implant chip…
FY22 ‘at least’ in line
The Pebble Group | 17/01/2023
The Pebble Group’s end-FY22 trading update discloses that both of its operations, Facilisgroup and Brand Addition, have traded well and that the…
Revised forecasts reflect macro concerns
Secure Trust Bank | 17/01/2023
We are adjusting our forecasts for Secure Trust Bank (STB) to better reflect the deteriorating economic outlook in the UK. We have raised our FY22 forecast…
Encouraging real-world data to support NanaBis
Medlab Clinical | 17/01/2023
Medlab Clinical has announced positive interim data from its real-world evidence study for NanaBis (Medcare observational study). The 12-month study comprised…
Local payment method growth accelerates
Boku | 17/01/2023
Boku expects to report FY22 revenue and EBITDA slightly ahead of our forecasts and closes the year with stronger than expected net cash. Total payment…
Planned dose-escalation commences in rGBM study
Midatech Pharma | 13/01/2023
Midatech has announced that following the completion of one month of treatment for the first patient enrolled in the MAGIC-G1 study (at a dose of 60uM),…
Good nine-month performance
Agrana | 13/01/2023
Agrana’s strong Q3, with its ability to push through cost increases, led to a good set of results for the first nine months of FY23 (9M23). Revenue…
Attractive growing income, innovatively funded
Impact Healthcare REIT | 13/01/2023
Impact Healthcare REIT (IHR) has invested £56m, on an accretive basis, in a portfolio of six quality care homes, to be operated by existing tenant…
Candidate selected to further bolster pipeline
IRLAB Therapeutics | 12/01/2023
IRLAB Therapeutics has announced that it has selected a drug candidate from its P003 discovery programme. The candidate, IRL1117, will now progress towards…
Core revenue growth offsets licensing decline
Games Workshop Group | 12/01/2023
Games Workshop Group’s (GAW’s) record H123 results included strong revenue recovery in Retail as COVID-19 restrictions eased, foreign exchange…
Revenue upside surprise for 2022
Basilea Pharmaceutica | 12/01/2023
Basilea has announced preliminary, unaudited revenue results for FY22, together with an operational update on its commercial and pipeline assets. Revenues…
FY23 starting well
The MISSION Group | 12/01/2023
The MISSION Group’s trading update outlines FY22 revenue a little ahead of market forecasts, with headline PBT of at least £7.6m edged ahead…
Multiple IoT deployment wins lead to upgrade
WANdisco | 12/01/2023
WANdisco’s (WAND’s) FY22 trading update confirms that both momentum and the pipeline remain exceptionally strong, with bookings of $127m (up…
Strong H222 with good visibility for FY23
XP Power | 12/01/2023
XP Power’s FY22 trading update confirmed that its H222 performance was significantly stronger than H122 as supply chain conditions improved. As expected,…
Sticking to the successful long-term strategy
Worldwide Healthcare Trust | 11/01/2023
Worldwide Healthcare Trust’s (WWH’s) two co-managers, Sven Borho and Trevor Polischuk at specialist investor OrbiMed, remain positive on the…
Manufacturing agreement with Lonza for CTIM-76
Context Therapeutics | 10/01/2023
Context Therapeutics has signed a manufacturing agreement with Lonza to develop CTIM-76 (active ingredient and final product form), its bispecific antibody…
New exploration and increased resources
KEFI Gold and Copper | 10/01/2023
This week, KEFI Gold and Copper (KEFI) released two updates pertaining to its exploration and development in Saudi Arabia. First, it announced an increase…
Starting 2023 with $6.6m telecom IoT win
WANdisco | 10/01/2023
WANdisco started 2023 on a strong note, announcing a $6.6m data-migration contract with a global telecom service provider. This is the third telecom provider…
Progressive outlook for CY23
AFT Pharmaceuticals | 10/01/2023
AFT Pharmaceuticals has presented its key CY22 highlights and strategic priorities for CY23 in a letter to investors. In addition to new product launches…
Cresemba milestone payment triggered
Basilea Pharmaceutica | 09/01/2023
Basilea has announced that it has received a sales-related milestone payment of CHF20m from its US licensing partner Astellas Pharma. This was triggered…
New public offering to support funding needs
OpGen | 09/01/2023
After completing the 1:20 share consolidation, OpGen has announced a $7.5m equity issue to be closed by 11 January 2023. As part of the offering, OpGen…
Vodafone Hungary acquisition finalised
4iG | 09/01/2023
4iG has finalised the agreement to buy a majority stake in Vodafone Hungary, with deal completion expected by the end of the month. This will make the…
A healthy recovery in portfolio income
Lowland Investment Company | 09/01/2023
The last 12 months have been difficult for Lowland Investment Company (LWI). Combined, the weakness in UK mid and small caps’ performance, UK corporate…
Context on no-fault settlement of litigation
Nanoco Group | 09/01/2023
Nanoco’s regulatory news release gives more information on its proposed settlement with Samsung and adds useful context in the face of speculation…
NC rollout to expand wheezo market potential
Respiri | 09/01/2023
Respiri has started patient onboarding for a major North Carolina (NC)-based healthcare organisation (the initial contract was signed in August 2022).…
Share consolidation to regain Nasdaq compliance
OpGen | 06/01/2023
Following a proposed share consolidation announced in November 2022, OpGen has effected a reverse stock split in the ratio of 1:20. This comes in the wake…
Production impresses at Tomingley
Alkane Resources | 06/01/2023
Alkane upgraded its FY23 guidance for gold production from 55,000–60,000oz to 62,000–70,000oz on 5 January. This follows H123 production at…
A catalyst-rich period ahead
Context Therapeutics | 06/01/2023
Context Therapeutics has presented a recap of key highlights of 2022 as well as strategic priorities and operational guidance for 2023. The past year saw…
Eye-catching revenue growth
Greggs | 05/01/2023
Greggs reported a strong acceleration in revenue growth in Q422 as revenue from new initiatives, digital and evening trading complemented anticipated space…
US contract wins and major renewal
Checkit | 05/01/2023
Checkit has made further progress with its US growth strategy, recently signing three new material contracts in the US with a total minimum value over…
Boosting presence in high-growth Cyber Security
Tinexta | 05/01/2023
Tinexta’s binding agreement to acquire an initial 20% stake in Defence Tech Holding (DTH) will provide a significant presence in a new client vertical…